Patents Assigned to Universite D'Auvergne
  • Patent number: 10632135
    Abstract: Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating E. coli induced inflammatory bowel diseases such as crohn's disease.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: April 28, 2020
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AUVERGNE, UNIVERSITE DES SCIENCES ET TECHNOLOGIES DE LILLE 1, UNIVERSITE DE NANTES, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Julie Bouckaert, Sebastien Gouin, Adeline Sivignon, Arlette Darfeuille-Michaud, Rostyslav Bilyy, Dimitri Alvarez-Dorta, Nao Yamakawa, Tetiana Dumych
  • Patent number: 10485811
    Abstract: Orally available compounds, a process for preparing the same and their uses as anti-adhesive drugs for treating E. coli induced inflammatory bowel diseases such as crohn's disease.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: November 26, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AUVERGNE, UNIVERSITE DES SCIENCES ET TECHNOLOGIES DE LILLE 1, UNIVERSITE DE NANTES, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Julie Bouckaert, Sebastien Gouin, Adeline Sivignon, Arlette Darfeuille-Michaud, Rostyslav Bilyy, Dimitri Alvarez-Dorta, Nao Yamakawa, Tetiana Dumych
  • Patent number: 10351539
    Abstract: The present invention concerns compounds of formula (I): their process of preparation and compositions thereof. The present invention also concerns their use as diagnostic agent in PET imaging.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: July 16, 2019
    Assignees: INSERM (Institut National de la Santé et de le Recherche Médicale), Université d'Auvergne Clermont 1
    Inventors: Claire Denis, Vincent Gaumet, Aurélien Vidal, Philippe Auzeloux, Jean-Claude Madelmont, Elisabeth Miot-Noirault, Jean-Michel Chezal
  • Patent number: 10273313
    Abstract: The present invention relates to multimeric mannosides, a process for preparing the same and their uses in medicine for treating Escherichia coli infections.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: April 30, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NANTES, UNIVERSITE DE PICARDIE JULES VERNE, UNIVERSITE LILLE 1-SCIENCES ET TECHNOLOGIES, UNIVERSITE D'AUVERGNE
    Inventors: Julie Bouckaert, Sebastien Gouin, David Deniaud, Rostyslav Bilyy, Tetiana Dumych, Adeline Sivignon, Arlette Darfeuille-Michaud
  • Patent number: 10238695
    Abstract: Composition containing a microorganism, preferably an Archaea, expressing a TMA methyltransferase and a TMA methyl group acceptor corrinoid protein, capable of metabolizing trimethylamine (TMA) in the presence of hydrogen in a human cavity, such as the intestine or the vagina, for use as a medicament for treating, reducing or eliminating TMA at the level of the human cavity. In addition, a composition containing a TMA methyltransferase and a TMA methyl group acceptor corrinoid protein. These compositions are of use for treating trimethylaminuria, for treating vaginal fluids in the case of bacterial vaginosis and for reducing or eliminating odours due to TMA. These compositions are also of use for reducing the level of plasma TMAO, for preventing the formation of atheroma plaques and/or for preventing cardiovascular diseases.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: March 26, 2019
    Assignee: UNIVERSITE D'AUVERGNE CLERMONT I
    Inventors: Jean-François Brugere, Guillaume Borrel, Paul William O'Toole, Corinne Malpuech-Brugere, Monique Alric
  • Patent number: 10011620
    Abstract: The present invention relates to a compound of formula (I) wherein: i is 0 or 1; j is 0 or 1; k is 0 or 1; R1 and R2 are in particular H, (C1-C12)alkyl, or a group of formula C(O)R; R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms; R3 is H and k=0 when j=1; or, when j=0, R3 is —C(O)R or -L-C(O)R; L, U and L? are linkers; wherein, when j=0, at least one of the groups R1; R2 and R3 comprises a radical R.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: July 3, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE D'AUVERGNE, UNIVERSITE DE MONTPELLIER
    Inventors: Philippe Brabet, David Cia, Laurent Guillou, Christian Hamel, Claire Vigor, Thierry Durand, Céline Crauste, Joseph Vercauteren
  • Patent number: 9728005
    Abstract: This method of calibration comprising the reconstruction of a 3D mapping of 3D landmarks of an environment on the basis of digital images of the environment captured by the computer-based vision system (10) during the movement of the craft (2) along a trajectory. It comprises the optimization of at least one 3D mapping corresponding to a first sequence of images by considering at least one extrinsic parameter and/or at least one intrinsic parameter and/or at least one parameter of poses and/or one parameter of 3D landmarks as constant and the optimization of at least one 3D mapping corresponding to a second sequence of images, longer than the first image sequence and including the first image sequence, by considering said at least one extrinsic parameter and/or said at least one intrinsic parameter and/or said at least one parameter of poses and/or said at least one parameter of 3D landmarks as variable so as to estimate it.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: August 8, 2017
    Assignees: Universite D' Auvergne Clermont I, Universite Blaise Pascal-Clermong II, Centre National De La Recherche Scientifique (C.N.R.S.)
    Inventors: Michel Dhome, Eric Royer, Maxime Lhuillier, Datta Ramadasan, Nadir Karam, Clément Deymier, Vadim Litvinov, Hicham Hadj Abdelkader, Thierry Chateau, Jean-Mare Lavest, François Marmoiton, Serge Alizon, Laurent Malaterre, Pierre Lebraly
  • Patent number: 9511045
    Abstract: This invention relates to riluzole for use in the treatment or prevention of adverse effects associated with the administration of anticancer agents having neurotoxic effects, such as, for example, platinum salts, taxanes and periwinkle alkaloids.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: December 6, 2016
    Assignee: UNIVERSITE D'AUVERGNE CLERMONT I
    Inventors: Jérôme Busserolles, Abdelkrim Alloui, Michel Lazdunski, Alain Eschalier
  • Patent number: 9448242
    Abstract: The present invention relates to treating and preventing pain. More particularly the present invention demonstrates the involvement of K2P potassium channels in the antalgic effect of morphine. The present invention therefore provides a screening method for identifying antalgics.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: September 20, 2016
    Assignee: UNIVERSITE D'AUVERGNE CLERMONT I
    Inventors: Alain Eschalier, Jéröme Busserolles, Abdelkrim Alloui, Michel Lazdunski
  • Patent number: 9212196
    Abstract: The invention relates to hypophosphorous acid derivatives of formula (I) wherein —X is H or OH, —R represents one or several radicals R1-R5, identical or different, two of R1-R5 optionally occupying the same position on the phenyl group, one to four of R1-R5 being H and the others being selected in the group comprising -0-(CH2)n—COOH; —S—(CH2)n—COOH; —NH—(CH2)n—COOH; -0-(CH,R?)—COOH; —O—(CH2)n—OH; OR?, —R? being a C1-C3 alkyl radical; —OH; —COOH; halogen, particularly —F, —CI, —Br, —I, —CF3; —OCF3; —N02; —CH?CH—COOH; —(CH2)n—COOH; O—(CH2)n—P03H2; O—(CF2)n—P03H2; O—(CH2)n—S03H; O—(CH2)n—CONHOH; O—(CH2)n-tetrazol; O—(CH2)n-hydroxyisoxazol—n=1 to 5, preferably 1-3; said hypophosrous acid derivatives being diastereoisomers or enantiomers.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: December 15, 2015
    Assignees: UNIVERSITE PARIS DESCARTES, UNIVERSITE D'AUVERGNE
    Inventors: Francine Acher, Jean-Philippe Pin, Cyril Goudet, Alain Eschalier, Jérôme Busserolles, Delphine Rigault, Isabelle Lemasson, Sara Cesarini, Bruno Commare
  • Patent number: 9125937
    Abstract: The present invention relates to the compound of formula (I): in which R1 represents a hydrogen atom, an optionally labelled halogen, a radionuclide or a Sn[(C1-C4)alkyl]3 group, Ar represents an aryl group or a heteroaryl group, R9 represents a hydrogen atom, a (C1-C4)alkyl group or forms together with the group R1—Ar a ring fused with the Ar group, A represents a group of formula (?) or (?): R3 and R4 independently represent a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or a group of formula (?): —Y—Z—W—R11??(?) wherein R11 represents an optionally labelled halogen, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen, a radionuclide, a —NO2 group, a —NR5R6 group, a —N+R5R6R7X? group, or a —OSO2R12 group, and their addition salts with pharmaceutically acceptable acids.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: September 8, 2015
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE D'AUVERGNE CLERMONT 1, LABORATORIES CYCLOPHARMA
    Inventors: Jean-Michel Chezal, Frederic Dolle, Jean-Claude Madelmont, Aurelie Maisonial, Elisabeth Miot-Noirault, Nicole Moins, Janine Papon, Bertrand Kuhnast, Bertrand Tavitian, Raphael Boisgard
  • Publication number: 20150189844
    Abstract: The invention relates to a method for obtaining a plant in which a homologous recombination event has occurred, preferably resulting in targeting gene insertion in the genome of said plant, by regeneration of the plant from in vitro culture.
    Type: Application
    Filed: July 19, 2013
    Publication date: July 9, 2015
    Applicants: Biogemma, Centre National de la Recherche Scientique, Université Blaise Pascal, Université d'Auvergne
    Inventors: Wyatt Paul, Ayhan Ayar, Charles White, Maria-Eugenia Gallego
  • Patent number: 8974789
    Abstract: An antagonist of the interaction between the Gp96 receptor and E. coli AIEC strains, for the prevention or treatment of inflammatory bowel disease. The antagonist is for specifically blocking or reducing the interaction between Gp96 receptor and the outer membrane vesicles (OMVs), typically the outer protein membrane OmpA of E. coli AIEC strains. The inventions provides for pharmaceutical compositions containing such an antagonist, which may be an antibody against gp96 or OmpA, or a gp96 or OmpA polypeptide. It may be combined to an antagonist of the interaction between the CEACAM6 receptor and E. coli AIEC strains, such as an anti-CEACAM6 antibody, a CEACAM6 polypeptide, or a mannoside or particle having a mannose unit. The invention also relates to a method for the diagnosis of inflammatory bowel disease, or of the determination of a predisposition of a person to develop inflammatory bowel disease.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: March 10, 2015
    Assignee: Universite d'Auvergne Clermont I
    Inventors: Arlette Darfeuille-Michaud, Paul Hofman, Nathalie Rolhion
  • Publication number: 20140378551
    Abstract: The invention relates to an analgesic composition containing memantine. According to the invention, such a composition is administered daily to a human patient having to undergo a surgical operation, over a period ranging from one day to a plurality of days before said surgical operation, in order to prevent and treat the development of post-operative neuropathic pain in this same patient.
    Type: Application
    Filed: October 10, 2012
    Publication date: December 25, 2014
    Applicant: Universite d'Auvergne
    Inventor: Gisele Pickering
  • Publication number: 20140142168
    Abstract: The present invention relates to a combination of a curcuminoid and a taxane for use in the treatment of a hormone-refractory prostate cancer (HRPC) in a patient in need thereof.
    Type: Application
    Filed: April 27, 2012
    Publication date: May 22, 2014
    Applicants: CENTRE JEAN PERRIN, Institut National de la Sante et de la Recherche Medicale (INSERM), UNIVERSITE D'AUVERGNE CLERMONT
    Inventors: Chantal Barthomeuf, Philippe Chollet, Eloise Planchat, Hervé Cure
  • Publication number: 20140093453
    Abstract: The present invention relates to the compound of formula (I): in which R1 represents a hydrogen atom, an optionally labelled halogen, a radionuclide or a Sn[(C1-C4)alkyl]3 group, Ar represents an aryl group or a heteroaryl group, R9 represents a hydrogen atom, a (C1-C4)alkyl group or forms together with the group R1—Ar a ring fused with the Ar group, A represents a group of formula (?) or (?): R3 and R4 independently represent a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkenyl group or a group of formula (?): —Y—Z—W—R11??(?) wherein R11 represents an optionally labelled halogen, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen, a radionuclide, a —NO2 group, a —NR5R6 group, a —N+R5R6R7X? group, or a —OSO2R12 group, and their addition salts with pharmaceutically acceptable acids.
    Type: Application
    Filed: September 19, 2013
    Publication date: April 3, 2014
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), LABORATOIRES CYCLOPHARMA, UNIVERSITE D'AUVERGNE CLERMONT 1, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Jean-Michel CHEZAL, Frederic DOLLE, Jean-Claude MADELMONT, Aurelie MAISONIAL, Elisabeth MIOT-NOIRAULT, Nicole MOINS, Janine PAPON, Bertrand KUHNAST, Bertrand TAVITIAN, Raphael BOISGARD
  • Patent number: 8476058
    Abstract: The invention relates to novel yeast strains, to the yeasts resulting from these strains, to a composition containing at least one Saccharomyces cerevisiae yeast and/or derivatives of a yeast having a particular interest as a food additive and/or probiotic and/or functional food and/or neutraceutic and/or functional ingredient and/or cosmeceutical and/or pharmaceutical active agent. The invention also relates to the use of the same in human and/or animal nutrition, or for the treatment or prevention of inflammatory diseases.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: July 2, 2013
    Assignees: Lesaffre et Compagnie, Universite du Droit et de la Sante Lille 2, Universite d 'Auvergne Clermont 1
    Inventors: Jean-Luc Simon, Georges Pignede, Pascal Vandekerckove, Pierre Desreumaux, Daniel Poulain, Arlette Darfeuille-Michaud, Adeline Sivignon
  • Publication number: 20130143753
    Abstract: The present invention relates to biomarkers allowing predicting breast tumor and solid tumor outcome using hypoxia related genes. More specifically, the present invention relates to a method for predicting the survival of a patient suffering from cancer, said method comprising the steps of (a) measuring the expression of at least five genes selected from the group consisting of GLUT1, PGK1, LDHA, ENO1, CAIX, NHERF1, TPI, AMF/GPI, VEGFA, TGFB3, ENG, LEP, EDN1, MDR1, AK3, MXR1, TGM2, CDH1, MMP2, CK1 9, VIM, CXCR4, UPAR, CATHD, CTGF, C0X2, MET, IGF-2, CCND1, EPO, NDRG1, BNIP3, NIX, ETS1, PHD2, TWIST1, DEC1, SNAH, CEBPA, CITED2, F0X03A, NUR77, BRCA1, PTEN, VHL and ERBB2 in a biological sample of said patient, and (b) analyzing the expression values to generate a risk score of relapse, wherein a risk score superior or equal to three is indicative of high risk of relapse and a risk score inferior or equal to two is indicative of a low risk of relapse.
    Type: Application
    Filed: March 1, 2010
    Publication date: June 6, 2013
    Applicants: ADELBIO, CENTRE JEAN PERRIN CENTRE DE LUTTE CONTRE LE CANCER DE LA REGION AUVERGNE, UNIVERSITE D'AUVERGNE CLERMONT I
    Inventors: Abderrahim El Guerrab, Anne Cayre, Fabrice Kwiatkowski, Maud Privat, Jean-Marc Rossignol, Fabrice Rossignol, Frederique Penault Llorca, Yves Jean Bignon
  • Publication number: 20130084292
    Abstract: An antagonist of the interaction between the Gp96 receptor and E. coli AIEC strains, for the prevention or treatment of inflammatory bowel disease. The antagonist is for specifically blocking or reducing the interaction between Gp96 receptor and the outer membrane vesicles (OMVs), typically the outer protein membrane OmpA of E. coli AIEC strains. The inventions provides for pharmaceutical compositions containing such an antagonist, which may be an antibody against gp96 or OmpA, or a gp96 or OmpA polypeptide. It may be combined to an antagonist of the interaction between the CEACAM6 receptor and E. coli AIEC strains, such as an anti-CEACAM6 antibody, a CEACAM6 polypeptide, or a mannoside or particle having a mannose unit. The invention also relates to a method for the diagnosis of inflammatory bowel disease, or of the determination of a predisposition of a person to develop inflammatory bowel disease.
    Type: Application
    Filed: April 15, 2011
    Publication date: April 4, 2013
    Applicant: UNIVERSITE D'AUVERGNE CLERMONT I
    Inventors: Arlette Darfeuille-Michaud, Paul Hofman, Nathalie Rolhion
  • Patent number: 8404707
    Abstract: The present invention relates to a series of novel imidazo[1,2-?]pyrrolo[3,2-c]pyridines (or also named 6H-1,3a,6-Tri-aza-?y-indacenes) and derivatives thereof, according to formula: (I); The present invention also relates to processes for the preparation of imidazo[1,2-?]pyrrolo[3,2-c]pyridines, their use as. a, medicine, their use to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with viruses belonging to the family of the Flaviviridae and more preferably infections with Bovine Viral Diarrhea virus (BVDV).
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: March 26, 2013
    Assignees: Universite d'Auvergne Clermont 1, Universite Francois Rabelais Tours, Kathlieke Universiteit Leuven
    Inventors: Johan Neyts, Jan Paeshuyse, Olivier Chavignon, Jean-Michel Chezal, Vincent Gaumet, Alain Gueiffier, Jean-Claude Teulade